HC Wainwright Upgrades Odyssey Therapeutics (NASDAQ:ODTX) to “Strong-Buy”

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by investment analysts at HC Wainwright to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports.

Several other analysts have also recently weighed in on ODTX. JPMorgan Chase & Co. raised their price objective on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen lowered shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. TD Cowen assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued a “buy” rating for the company. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Finally, Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Odyssey Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $35.75.

Odyssey Therapeutics Price Performance

NASDAQ ODTX opened at $25.98 on Thursday. The stock has a market cap of $1.25 billion and a price-to-earnings ratio of -3.84. The company has a fifty day moving average of $19.57. Odyssey Therapeutics has a 12 month low of $15.10 and a 12 month high of $28.00.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, research analysts anticipate that Odyssey Therapeutics will post -5.97 EPS for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.